GTC Biotherapeutics, Ovation to collaborate over anti-coagulant

06/24/2008 | Forbes · Reuters

GTC Biotherapeutics has entered into a deal worth up to $257 million with Ovation Pharmaceuticals to develop and market ATryn, an experimental treatment for hereditary anti-thrombin deficiency, in the U.S. GTC could receive up to $9 million in milestone payments upon approval of the drug, which has obtained orphan designation and fast-track status from the FDA.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA